renal cell carcinoma
Everolimus improves progression-free survival for patients with rare pancreatic cancer
Houston – In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (…
Research provides new kidney cancer clues
Grand Rapids, Mich. (January 19, 2011) — In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer. The gene — cal…
Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
Richmond, Va. (Dec. 15, 2010) — Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown …
Scientists report discovery of cancer-causing gene in childhood kidney tumor
In a discovery sparked by a routine check-up of a young cancer survivor, researchers at Dana-Farber Cancer Institute and Children’s Hospital Boston have identified a gene responsible for a childhood form of the kidney tumor papillary renal cell carcinoma (PRCC).
Minimally invasive treatment successfully destroys kidney tumors
A minimally invasive, experimental treatment is proving successful in removing small kidney tumors from appropriate patients, report researchers from Massachusetts General Hospital (MGH). In a study in the February 2003 issue of Radiology, the MGH team describes how a technique called radiofrequency ablation (RFA) destroyed all renal cell carcinoma (RCC) tumors less than 3 cm in size and some larger tumors, depending on their location. The most common form of kidney cancer, RCC will be diagnosed in almost 32,000 Americans this year and is most frequently treated with surgical removal through either an open or laparoscopic procedure.